VFA
DNTH icon

Values First Advisors’s Dianthus Therapeutics DNTH Stock Holding History

Values First Advisors’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,365
Closed -$331K – 130
2019
Q4 		$331K Buy
+1,365
New +$255K 0.32% 92

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Values First Advisors's DNTH Position: Q1 2020 in Review

Values First Advisors sold out of Dianthus Therapeutics (DNTH) in Q1 2020, closing a stake of 1,365 shares — an estimated $331K sold.

Values First Advisors first reported a position in DNTH in Q4 2019 and held it in 1 quarter. The position peaked at $331K in Q4 2019. 72 funds tracked by Wall St. Rank hold DNTH as of Q1 2020.

  • Values First Advisors reported no remaining Dianthus Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Values First Advisors sold 1,365 Dianthus Therapeutics shares in Q1 2020, an estimated $331K.
  • Values First Advisors first reported a position in Dianthus Therapeutics in Q4 2019 and held it in 1 quarter.
  • Values First Advisors's Dianthus Therapeutics position peaked at $331K in Q4 2019.
  • 72 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2020.

Based on Values First Advisors's 13F filing for Q1 2020, filed 9 Jan 2023.